Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?

Executive Summary

Bluebird and Celgene are focused on moving bb2121 into earlier lines of multiple myeloma therapy. Positive early data was was the opening headliner at ASCO, showing PFS improvements of about a year in heavily pre-treated patients – meeting expectations, though not overwhelming.

Advertisement

Related Content

Bluebird Lays Some New Eggs, But They'll Take Time To Hatch
CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market
ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight
Celgene's Focus On Execution Pays Off, But Follow-Through Is Key
Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy
Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications
CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say
ASCO 2018: Optimism As Industry Resets And Looks To What Is Next
Janssen Exec On Speeding Earlier Myeloma Interventions To Market With Key Biomarker
Celgene's CAR-T Leadership Goals Advance At ASH 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123190

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel